Cardiovascular event

News Hour: Adults taking low-dose aspirin — whether to prevent recurrent cardiovascular events or to prevent the first event — face an increased risk for CV events if they stop treatment, finds an observational study in Circulation....

News Hour: Tresiba® demonstrated no increased risk of major cardiovascular (CV) events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial. DEVOTE is a long-term, a multinational, randomized,...